Share Price, page-11862

I wonder when these additional indications will be known.The first mention of them i can seem to find is in the investor presentation on 15/05 (nearly right on 4 months ago)
Looking back through other announcements i note that on 06/03/2020 it was announced that we had "compelling results for NNZ-2591 dose -ranging study in PM syndrome model". Further, it detailed the study of the knockout mouse model was for a duration of 6 weeks of treatment with 4 dose levels that built on 3 weeks of treatment. It was noted better efficay after 6 weeks compared with 3 at the same dose level.
I am unsure if these other indicications would require the same foundation dose level however in the above announcement it was noted that the "study builds on the positive results previously reported by Neuren in a study of 3 weeks’ treatment with NNZ-2591 compared with placebo, which formed the basis for the Orphan Drug designation granted by the US Food and Drug Administration (FDA)." Based on this perhaps it is required to get orphan designation.
Even so, that would be 9 weeks all up. We must be very close to having them announced.